<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04870905</url>
  </required_header>
  <id_info>
    <org_study_id>ICRT-001</org_study_id>
    <nct_id>NCT04870905</nct_id>
  </id_info>
  <brief_title>Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma: a Phase 2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial intends to enroll patients with T4N1 or T1-4N2-3 (AJCC 8th)&#xD;
      locoregionally-advanced nasopharyngeal carcinoma (LANPC). All the Patients will receive 3&#xD;
      cycles of induction chemotherapy with docetaxel and cisplatin and cisplatin based concurrent&#xD;
      chemoradiotherapy (CCRT) plus adjuvant immunotherapy (tisleilizumab). All patients will&#xD;
      receive intensity-modulated radiotherapy (IMRT). Tisleilizumab will begin 4-6 weeks after&#xD;
      CCRT and continue every 3 weeks for 12 cycles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free survival (FFS)</measure>
    <time_frame>3 years</time_frame>
    <description>From randomization to the date of locoregional failure, distant failure, or death from any cause.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Nasopharyngeal Neoplasms</condition>
  <arm_group>
    <arm_group_label>ICRT arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tis-U-Sol</intervention_name>
    <description>Tislelizumab 200mg will be given every 3 weeks for 12 cycles</description>
    <arm_group_label>ICRT arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients with histologically confirmed nasopharyngeal carcinoma. Stage T4N1 or T1-4N2-3&#xD;
        (AJCC 8th). Eastern Cooperative Oncology Group performance status ≤1. Adequate marrow&#xD;
        function: neutrocyte count≥1.5×10e9/L, hemoglobin ≥90g/L and platelet count ≥100×10e9/L.&#xD;
&#xD;
        Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) ≤2.5×upper limit of normal&#xD;
        (ULN), and bilirubin ≤ 1.5×ULN.&#xD;
&#xD;
        Adequate renal function: creatinine clearance rate ≥ 60 ml/min (Cockcroft-Gault formula).&#xD;
&#xD;
        Patients must be informed of the investigational nature of this study and give written&#xD;
        informed consent.&#xD;
&#xD;
        Women of childbearing potential (WOCBP) who are sexually active must be willing to adhere&#xD;
        to effective contraception during treatment and for 1 year after the last dose of study&#xD;
        drug. Men who are sexually active with WOCBP must be willing to adhere to effective&#xD;
        contraception during treatment and for 1 year after the last dose of the study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA &gt;1×10e3 copies/ml or&#xD;
        200IU/ml;Hepatitis C virus (HCV) antibody positive Has active autoimmune disease, except&#xD;
        type I diabetes, hypothyroidism treated with replacement therapy, and skin disease that&#xD;
        doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia).&#xD;
&#xD;
        Has any condition that required systemic corticosteroid (equivalent to prednisone &gt;10mg/d)&#xD;
        or other immunosuppressive therapy within 28 days before informed consent. Patients&#xD;
        received systemic corticosteroid equivalent to prednisone ≤10mg/d, inhale or topical&#xD;
        corticosteroid will be allowed.&#xD;
&#xD;
        Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with&#xD;
        adequately treated active TB over 1 year ago will be allowed.&#xD;
&#xD;
        Has a known history of interstitial lung disease. Heart disease that is not well&#xD;
        controlled,including symptomatic heart failure, unstable angina, myocardial infarction.&#xD;
&#xD;
        Is pregnant or breastfeeding. Prior malignancy within 5 years, except in situ cancer,&#xD;
        adequately treated non-melanoma skin cancer, and papillary thyroid carcinoma.&#xD;
&#xD;
        Has known allergy to large molecule protein products or any compound of tisleilizumab.&#xD;
&#xD;
        Has a known history of human immunodeficiency virus (HIV) infection. Active infection&#xD;
        requiring systemic therapy. A history of psychotropic substance abuse, alcohol or drug&#xD;
        abuse Any other condition, including mental illness or domestic/social factors, deemed by&#xD;
        the investigator to be likely to interfere with a patient's ability to sign informed&#xD;
        consent, cooperate and participate in the study, or interferes with the interpretation of&#xD;
        the results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal investigator Principal investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuan yawei</last_name>
    <phone>13316085871</phone>
    <email>yuanyawei@gzhmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuan yawei</last_name>
      <email>yuanyawei@gzhmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lee AW, Ngan RK, Tung SY, Cheng A, Kwong DL, Lu TX, Chan AT, Chan LL, Yiu H, Ng WT, Wong F, Yuen KT, Yau S, Cheung FY, Chan OS, Choi H, Chappell R. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015 Apr 15;121(8):1328-38. doi: 10.1002/cncr.29208. Epub 2014 Dec 19. Erratum in: Cancer. 2020 Jan 15;126(2):454-455.</citation>
    <PMID>25529384</PMID>
  </reference>
  <reference>
    <citation>Lv X, Cao X, Xia WX, Liu KY, Qiang MY, Guo L, Qian CN, Cao KJ, Mo HY, Li XM, Li ZH, Han F, He YX, Liu YM, Wu SX, Bai YR, Ke LR, Qiu WZ, Liang H, Liu GY, Miao JJ, Li WZ, Lv SH, Chen X, Zhao C, Xiang YQ, Guo X. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 May;22(5):716-726. doi: 10.1016/S1470-2045(21)00075-9. Epub 2021 Apr 12.</citation>
    <PMID>33857411</PMID>
  </reference>
  <reference>
    <citation>Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019 Jul 6;394(10192):64-80. doi: 10.1016/S0140-6736(19)30956-0. Epub 2019 Jun 6. Review.</citation>
    <PMID>31178151</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, Ma J. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19;381(12):1124-1135. doi: 10.1056/NEJMoa1905287. Epub 2019 May 31.</citation>
    <PMID>31150573</PMID>
  </reference>
  <reference>
    <citation>Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016 Nov;17(11):1509-1520. doi: 10.1016/S1470-2045(16)30410-7. Epub 2016 Sep 27.</citation>
    <PMID>27686945</PMID>
  </reference>
  <reference>
    <citation>Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, Zhang Y, Chen L, Zhou N, Zhao Y, Hou X, Yang Q, Zhang L. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018 Oct;19(10):1338-1350. doi: 10.1016/S1470-2045(18)30495-9. Epub 2018 Sep 10.</citation>
    <PMID>30213452</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 1, 2021</study_first_submitted>
  <study_first_submitted_qc>May 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Yuan yawei</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

